“It’s hard to say that there’s no causal relationship.”
EMA “I can’t conclude yet…review is in progress”
viewer
Amid reports of the formation of blood clots after receiving a vaccine to prevent the novel coronavirus infection (Corona 19) jointly developed by multinational pharmaceutical company AstraZeneca (AZ) and Oxford University in the UK, a senior member of the European Medicines Agency (EMA) said AstraZeneca vaccine and rare They commented that there is a clear causal relationship between thrombosis. However, EMA expressed a cautious position, saying that it has not yet reached a conclusion.
Marco Cavaleri, head of vaccine strategy at EMA, told Il Mesazero in Italy on the 6th (local time), “It is getting harder to say that there is no causal relationship between the AZ vaccine and the very rare thrombosis associated with low platelets There is” he said. “It’s clear in my opinion that (this symptom) is related to vaccination, but we still don’t know what caused this reaction,” he explained.
Cavaleri said the EMA will sooner or later make a comment acknowledging the link between the AZ vaccine and rare thrombosis. However, these cases are very rare, reaffirming EMA’s previous position that the benefits of vaccination outweigh the risk of side effects.
However, in response to Cavalelli’s remarks, EMA has not yet reached a conclusion, and has made an official position that a related review is underway. An EMA spokesperson said the briefing will be held as soon as the review is finalized, and that the time will be on the 7th or 8th.
Previously, EMA concluded last month that AZ vaccination was not associated with an increased risk of common blood clots, but further analysis is required regarding specific blood clots, such as disseminated intravascular coagulation disorder (DIC) and cerebral sinus thrombosis (CVST), which occur very rarely. I have said it is necessary. EMA is conducting an evaluation of the safety committee in this regard, and is expected to make the latest recommendations during the entire meeting, which runs from this day to the 9th.
EMA and the World Health Organization (WHO) have repeatedly revealed that the benefit of the AZ vaccine in the prevention of COVID-19 outweighs the risk of side effects, but safety concerns seldom subside as thrombosis cases continue to emerge. In recent years, some European countries recommend restricting AZ vaccination or cross vaccination with other vaccinations for those under the age of 60, and the UK is also known to be considering restricting vaccinations to younger populations.
/ Reporter Kim Kyung-rim [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >